<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="304">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558114</url>
  </required_header>
  <id_info>
    <org_study_id>RACHE</org_study_id>
    <nct_id>NCT02558114</nct_id>
  </id_info>
  <brief_title>Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.</brief_title>
  <official_title>Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy, safety and recurrence rate of two
      therapeutic strategies with ribavirin in patients with chronic hepatitis E and severe acute
      hepatitis E: fixed duration of treatment for 12 weeks vs variable duration depending on the
      viremia within 4 weeks of the start of treatment (12 vs 24 weeks).

      The purpose of the study is also improve the safety of treatment with Ribavirin by
      optimizing dose adjusted to renal function, plasma levels of drug and hemoglobin.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained virological response measured by HEV RNA</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HEV RNA undetectable at 48 weeks after end of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Hepatitis E</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive ribavirin during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive:
ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)
- ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or greater than 18 years.

          -  To comply with any of the following diagnoses:

          -  chronic Hepatitis E: HEV RNA detectable in patients with elevated transaminase levels
             for at least 6 months and / or HEV RNA detectable in two separated determinations by
             an interval of six months .

          -  severe acute Hepatitis E: alanine aminotransferase (ALT) levels greater than 10 times
             the normal limit, with HEV RNA positive, and signs of acute liver injury
             (International normalized ratio(INR&gt; 1.5)); or with extrahepatic manifestations or
             liver failure in patients with previous liver disease.

          -  Signed informed consent

        Exclusion Criteria:

          -  Terminal illness with a expected life expectancy of less than 6 months

          -  Patients with contraindications for treatment with Ribavirin:

          -  pregnancy or lactation.

          -  Severe hepatic impairment or decompensated cirrhosis.

          -  hemoglobinopathies (thalassemia, sickle cell anemia).

          -  history of severe pre-existing cardiac disease, including unstable heart disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitari vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mar Riveiro, MD</last_name>
      <phone>+34 932746240</phone>
      <email>mar.riveiro@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rafael Esteban, MD</last_name>
      <phone>+34 932746240</phone>
    </contact_backup>
    <investigator>
      <last_name>Mar riveiro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>rafael esteban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 22, 2015</lastchanged_date>
  <firstreceived_date>September 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis E</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
